Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–70
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Overtly healthy males or females, as determined by medical history and physical examination
* Male participants will be sterile
* Female participants must not be of childbearing potential
You may not be if
Have known allergies to abemaciclib, related compounds, or any components of the formulation
Have an abnormality in the 12-lead electrocardiogram (ECG) including a Fridericia's corrected QT interval (QTcF) greater than 450 milliseconds (ms) (males) or greater than 470 ms (females)
Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
Have a gastrointestinal disorder causing clinically significant symptoms such as nausea, vomiting, and diarrhea, or malabsorption syndromes, or constipation
Additional Exclusion Criterion for Participants Enrolled in Cohort 2:
Have a known hypersensitivity to loperamide hydrochloride or to any of the excipients
Clareo Health | A Study of Abemaciclib in Healthy Participants
